Sanofi-Aventis S.A. http://www.alacrastore.com/company-snapshot/Sanofi_Aventis_S_A-2019477 Thursday, July 24, 2008 4:11:39 PM 2019477 Sanofi-Aventis S.A. en AlacraStore RSS Builder 1.0 30 AUSTRALIA - sanofi-aventis Australia Pty Ltd, a wholly-owned unit of Sanofi-Aventis SA, agreed to acquire the pharmacy services and consumer business of Symbion Health Ltd, a pharmaceuticals manufacturer and wholesaler, from Primary Health Care Ltd, for ### mil Australian dollars ($###.### mil US) in cash. The transaction was approved by regulatory authorities.7/22/2008 6:51:14 PM80095Q87757M80117M74188Nsanofi-aventis Australia Pty LtdSymbion Health Ltd-Pharmacy Services & Consumer BusinessSanofi-Aventis SAPrimary Health Care Ltdhttp://www.alacrastore.com/storecontent/Thomson_M%26A/sanofi_aventis_Australia_acquires_Symbion_Health_Pharmarcy_Svcs_from_Primary_Health_Care_Ltd-1997114040sdc/19971140401997114040Copyright © 2008, Thomson Financial, All Rights ReservedDrugsAustraliaPharmaceutical preparations2834FFForeignSubsidiary2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8731:Commercial physical and biological researchDrugsAustraliaPharmaceutical preparations2834FFForeignSubsidiary1029667001Mnfr pharmPvd med,health svcsCashCash OnlyAssets85954001Jul 22 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.00000sanofi-aventis Australia PtyLtd, headquartered inMacquarie Park, New SouthWales, manufactures anddevelops pharmaceuticalproducts specifically fortherapeutic areas such ascardiovascular diseases, bonediseases, oncology, centralnervous system, diabetes,allergies and infectiousdiseases and vaccines. Thegroup operates research anddevelopment centers in threecontinents, and maintainsoffices in all Australianstates, as well as inAuckland, New Zealand.sanofi-aventis Australia Pty Ltd, headquartered in MacquariePark, New South Wales, manufactures and developspharmaceutical products specifically for therapeutic areassuch as cardiovascular diseases, bone diseases, oncology,central nervous system, diabetes, allergies and infectiousdiseases and vaccines. The group operates research anddevelopment centers in three continents, and maintainsoffices in all Australian states, as well as in Auckland,New Zealand.sanofi-aventis Australia Pty Ltd, headquartered in Macquarie Park, New South Wales, manufactures and develops pharmaceutical products specifically for therapeutic areas such as cardiovascular diseases, bone diseases, oncology, central nervous system, diabetes, allergies and infectious diseases and vaccines. The group operates research and development centers in three continents, and maintains offices in all Australian states, as well as in Auckland, New Zealand.1.000002.000003.000004.000005.000006.00000The pharmacy services andconsumer business of SymbionHealth Ltd, located inAustralia, is engaged in themanufacture and wholesale ofpharmaceuticals.The pharmacy services and consumer business of SymbionHealth Ltd, located in Australia, is engaged in themanufacture and wholesale of pharmaceuticals.The pharmacy services and consumer business of Symbion Health Ltd, located in Australia, is engaged in the manufacture and wholesale of pharmaceuticals.0.000000.000000.000000.00000YAustralian Dollar21 Jul 08Mon, 21 Jul 2008 00:00:00 ESTDate Announced: 07/21/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.00000560 Australian Dollar560.000000.00000560 Australian Dollar560.000000.000000.000000.000000.00000560.00000560 Australian Dollar0.97700N273.136000.000000.000000.000000.000000.00000547.06400547.064000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.00000AUSTRALIA - sanofi-aventisAustralia Pty Ltd, awholly-owned unit ofSanofi-Aventis SA, agreed toacquire the pharmacy servicesand consumer business ofSymbion Health Ltd, apharmaceuticals manufacturerand wholesaler, from PrimaryHealth Care Ltd, for 560 milAustralian dollars ($547.064mil US) in cash. Thetransaction was approved byregulatory authorities.AUSTRALIA - sanofi-aventis Australia Pty Ltd, a wholly-owned unit of Sanofi-Aventis SA, agreed to acquire the pharmacy services and consumer business of Symbion Health Ltd, a pharmaceuticals manufacturer and wholesaler, from Primary Health Care Ltd, for 560 mil Australian dollars ($547.064 mil US) in cash. The transaction was approved by regulatory authorities.AUSTRALIA - sanofi-aventis Australia Pty Ltd, a wholly-owned unit of Sanofi-Aventis SA,agreed to acquire the pharmacy services and consumer business of Symbion Health Ltd, apharmaceuticals manufacturer and wholesaler, from Primary Health Care Ltd, for 560 milAustralian dollars ($547.064 mil US) in cash. The transaction was approved by regulatoryauthorities.AUSTRALIA - sanofi-aventis Australia Pty Ltd, a wholly-owned unit of Sanofi-Aventis SA, agreed to acquire the pharmacy services and consumer business of Symbion Health Ltd, a pharmaceuticalsmanufacturer and wholesaler, from Primary Health Care Ltd, for 560 mil Australian dollars ($547.064 mil US) in cash. The transaction was approved by regulatory authorities.AUSTRALIA - sanofi-aventis Australia Pty Ltd, a wholly-owned unit of Sanofi-Aventis SA, agreed to acquire the pharmacy services andconsumer business of Symbion Health Ltd, a pharmaceuticals manufacturer and wholesaler, from Primary Health Care Ltd, for 560 milAustralian dollars ($547.064 mil US) in cash. The transaction was approved by regulatory authorities.Caliburn Partnership Pty Ltd1.00000$ 547.064 - Caliburn Partnership Pty Ltd - Adv0.00000Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations5122:Drugs, drug proprietaries, and druggists' sundries337714003New YorkFrance2834ForeignPublicSNY6324:Hospital and medical service plans6512:Operators of nonresidential buildings8011:Offices and clinics of doctors of medicine8062:General medical and surgical hospitals8071:Medical laboratories8093:Specialty outpatient facilities, nec8099:Health and allied services, nec493530001AustraliaAustralia8099ForeignPublicPRY547.06400560.00000547.06400273.13600Mallesons Stephen JaquesDeal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26595435newstex/PRN-0005-26595435xml LONDON, Jul. ##, #### (PRNewswire delivered by Newstex) -- Silence Therapeutics plc (London AIM: SLN), a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental...070000000700500004000000040020000400200604002001040160000401603107014000070140120701400807001000070010040700300007003001020000000200200002002008130000001301000013010005130050001300500113002000130020057/11/2008 10:16:42 AM18000000180180001802000019000000190020001900200719002018PR Newswire USPRN-0005-26595435ALNYLAM PHARMACEUTICALS, INC.QUARK BIOTECH INC.SANOFI-AVENTISSILENCE THERAPEUTICS PLCALNYQURKSLNCFSNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MCOM-0006-26357116newstex/MCOM-0006-26357116xml Jul. #, #### (M# Communications Ltd. delivered by Newstex) -- Danish biopharmaceutical company Bavarian Nordic A/S (OMX Copenhagen: BAVA) said on Monday (## June) that it has filed a patent infringement suit against the UK company Oxford...04000000040020000400200604016000040160310200000002002000020020087/1/2008 5:17:06 AM18000000180180001900000019002000190020071900201419002018M2 Nordic Business ReportMCOM-0006-26357116SANOFI-AVENTISSNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26340771newstex/PRN-0005-26340771xml Denmark, Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Bavarian Nordic has filed a patent infringement suit against Oxford BioMedica plc, Biomedica, Inc., and Oxford BioMedica Ltd., in the United States District Court...0200000002002000020020080400000004016000040160310700000007003000070030066/30/2008 2:37:10 PM1800000018018000PR Newswire USPRN-0005-26340771SANOFI-AVENTISSNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-26338956newstex/HUG-0001-26338956xml Jun. ##, #### (Hugin AS delivered by Newstex) -- Bavarian Nordic has filed a patent infringement suit against Oxford BioMedica plc, Biomedica, Inc., and Oxford BioMedica Ltd., in the United States District Court of the Southern District...0200000002002000020020080400000004016000040160316/30/2008 12:17:55 PM1800000018018000Hugin ASHUG-0001-26338956SANOFI-AVENTISSNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/CNG-0001-26158691newstex/CNG-0001-26158691xml Jun. ##, #### (CompanyNewsGroup delivered by Newstex) -- BioAlliance Pharma extends its Loramyc(TM) License to China through an agreement with NovaMed (NASDAQ:NOVA) PharmaceuticalsParis, June ##th, #### - BioAlliance Pharma SA (Euronext...040000000400200004002006040160000401601307000000070140000701401207014008070030000700300107001000070010041300000013010000130100056/23/2008 2:17:34 AM180000001802200018020000180150001900000019002000190020091900201319002004190020071900201819002001Hugin Southern EuropeCNG-0001-26158691NOVAMED INCPFIZER INCSANOFI-AVENTISNOVAPFESNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26158274newstex/MW-0001-26158274xml PARIS, Jun. ##, #### (Marketwire delivered by Newstex) -- PARIS -- (MARKET WIRE) -- ##/##/## -- BioAlliance Pharma extends its Loramyc(TM) License to China through an agreement with NovaMed Pharmaceuticals Paris, June ##th, #### -...040000000400200004002006040160000401601307000000070140000701401207014008070030000700300107001000070010041300000013010000130100056/23/2008 2:17:34 AM180000001802200018020000180150001900000019002000190020091900201319002004190020071900201819002001MarketwireMW-0001-26158274NOVAMED INCPFIZER INCSANOFI-AVENTISNOVAPFESNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26134938newstex/PRN-0005-26134938xml KNOXVILLE, Tenn., Jun. ##, #### (PRNewswire delivered by Newstex) -- TeamHealth announced today that Heidi S. Allen has joined TeamHealth as senior vice president and general counsel, reporting directly to the CEO. Ms. Allen is assuming...09000000090150000400000004006000040060056/20/2008 6:15:31 PM1800000018007000190000001900100019001042PR Newswire USPRN-0005-26134938SANOFI-AVENTISSNYNewsNewstexNETHERLANDS - Sanofi-Aventis SA of France planned to launch a challenging tender offer to acquire the remaining ##.##% interest, or ##.### mil ordinary shares, which it did not already own, in Zentiva NV (ZN), an Amsterdam-based manufacturer of pharmaceuticals, for ##.### euros (#,### Czech koruna/$##.### US) in cash per share, or a total value of #.### bil euros (##.### bil koruna/$#.### bil). Originally, Anthiarose Ltd of Cyprus, a wholly-owned unit of Prvni Privatizacni Fond AS, planned to launch an unsolicited tender offer to acquire the remaining ##.#% interest, which it did not already own, in ZA. The offer was conditioned upon at least ##% of ZAs shares being tendered. The transaction was subject to regulatory approvals.6/19/2008 5:24:22 PM80117M98942R80117M98942RSanofi-Aventis SAZentiva NVSanofi-Aventis SAZentiva NVhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Sanofi_Aventis_SA_acquires_Zentiva_NV-1988087040sdc/19880870401988087040Copyright © 2008, Thomson Financial, All Rights ReservedNew YorkDrugsFrancePharmaceutical preparations2834FFForeignPublicSNY2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8731:Commercial physical and biological researchLondonDrugsNetherlandsPharmaceutical preparations2834FFForeignPublicZEND337714003Mnfr pharmMnfr pharmCashCash OnlyOrdinary Share830926002Jun 19 200812.967000.82900185.40600174.05800284.62400173.34500149.37300109.17700492.272000.718001.93000123.024001.7700067.1970093.73300878.51600216.932001964.63800EUR31 Dec 070.000007684.333000.0000040957.79900100747.54300EURO31 Mar 0831 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.577001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.00000Sanofi-Aventis SA, based inParis, France, manufacturesand develops pharmaceuticalsfor the following therapeuticareas: cardiovascular,thrombosis, central nervoussystem, oncology, metabollicdisorders, internal medicine,and vaccines. Its productsportfolio includes Lovenox,Plavix, Stilnox, Taxotere,Eloxatine, Lantus, Copaxone,Aprovel, Tritace, Allegra,Amaryl, Xatral, Actonel, andDepakine.Sanofi-Aventis SA, based in Paris, France, manufactures anddevelops pharmaceuticals for the following therapeuticareas: cardiovascular, thrombosis, central nervous system,oncology, metabollic disorders, internal medicine, andvaccines. Its products portfolio includes Lovenox, Plavix,Stilnox, Taxotere, Eloxatine, Lantus, Copaxone, Aprovel,Tritace, Allegra, Amaryl, Xatral, Actonel, and Depakine.Sanofi-Aventis SA, based in Paris, France, manufactures and develops pharmaceuticals for the following therapeutic areas: cardiovascular, thrombosis, central nervous system, oncology, metabollic disorders, internal medicine, and vaccines. Its products portfolio includes Lovenox, Plavix, Stilnox, Taxotere, Eloxatine, Lantus, Copaxone, Aprovel, Tritace, Allegra, Amaryl, Xatral, Actonel, and Depakine.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.00000Zentiva NV, located inAmsterdam, Netherlands,manufactures prescriptionpharmaceuticals intended forfinal consumption, includingbiotech products andantibiotics. It has operationsin Czech Republic, Turkey,Romania, Slovakia, Poland,Russia, Bulgaria, the Ukraineand the Baltic countries.Products of the company areintended for pain treatment,cardiovascular diseases,disorders of central nervoussystem, digestion system,urinary tract and genitalsystem, and treatment ofrespiratory diseases. The keyproduct in the area of foodsupplements are vitaminpreparations. The companyemploys around 6500 employees.Zentiva NV, located in Amsterdam, Netherlands, manufacturesprescription pharmaceuticals intended for final consumption,including biotech products and antibiotics. It hasoperations in Czech Republic, Turkey, Romania, Slovakia,Poland, Russia, Bulgaria, the Ukraine and the Balticcountries. Products of the company are intended for paintreatment, cardiovascular diseases, disorders of centralnervous system, digestion system, urinary tract and genitalsystem, and treatment of respiratory diseases. The keyproduct in the area of food supplements are vitaminpreparations. The company employs around 6500 employees.Zentiva NV, located in Amsterdam, Netherlands, manufactures prescription pharmaceuticals intended for final consumption, including biotech products and antibiotics. It has operations in Czech Republic, Turkey, Romania, Slovakia, Poland, Russia, Bulgaria, the Ukraine and the Baltic countries. Products of the company are intended for pain treatment, cardiovascular diseases, disorders of central nervous system, digestion system, urinary tract and genital system, and treatment of respiratory diseases. The key product in the area of food supplements are vitamin preparations. The company employs around 6500 employees.0.000000.000000.0000038.14000YEURO18 Jun 08Wed, 18 Jun 2008 00:00:00 ESTDate Announced: 06/18/2008Date Effective:MergerFriendlyPending0.000000.000000.000002256.518000.0000043.57400Price/Share0.000001248.31 EURO1248.305001654.287001850.54 EURO1850.536000.000000.0000067.5670067.567001850.536001850.54 EURO1.55100N989.498000.000000.000000.000000.000000.000001935.657001935.6570014.0670019.1880028.9170052.941004.049000.0000024.8800075.1200020.9470031.569006.9980057.796004.4210021.9580038.987002.982000.000000.2050012.367000.508003499.020000.000000.00000733.339000.00000554.9830015.6540037.01900-16.8400011.378001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.00000NETHERLANDS - Sanofi-AventisSA of France planned to launcha challenging tender offer toacquire the remaining 75.12%interest, or 28.648 milordinary shares, which it didnot already own, in Zentiva NV(ZN), an Amsterdam-basedmanufacturer ofpharmaceuticals, for 43.574euros (1,050 Czechkoruna/$67.568 US) in cash pershare, or a total value of1.248 bil euros (30.080 bilkoruna/$1.936 bil).Originally, Anthiarose Ltd ofCyprus, a wholly-owned unit ofPrvni Privatizacni Fond AS,planned to launch anunsolicited tender offer toacquire the remaining 80.9%interest, which it did notalready own, in ZA. The offerwas conditioned upon at least50% of ZAs shares beingtendered. The transaction wassubject to regulatoryapprovals.NETHERLANDS - Sanofi-Aventis SA of France planned to launch a challenging tender offer to acquire the remaining 75.12% interest, or 28.648 mil ordinary shares, which it did not already own, in Zentiva NV (ZN), an Amsterdam-based manufacturer of pharmaceuticals, for 43.574 euros (1,050 Czech koruna/$67.568 US) in cash per share, or a total value of 1.248 bil euros (30.080 bil koruna/$1.936 bil). Originally, Anthiarose Ltd of Cyprus, a wholly-owned unit of Prvni Privatizacni Fond AS, planned to launch an unsolicited tender offer to acquire the remaining 80.9% interest, which it did not already own, in ZA. The offer was conditioned upon at least 50% of ZAs shares being tendered. The transaction was subject to regulatory approvals.NETHERLANDS - Sanofi-Aventis SA of France planned to launch a challenging tender offer toacquire the remaining 75.12% interest, or 28.648 mil ordinary shares, which it did notalready own, in Zentiva NV (ZN), an Amsterdam-based manufacturer of pharmaceuticals, for43.574 euros (1,050 Czech koruna/$67.568 US) in cash per share, or a total value of 1.248bil euros (30.080 bil koruna/$1.936 bil). Originally, Anthiarose Ltd of Cyprus, awholly-owned unit of Prvni Privatizacni Fond AS, planned to launch an unsolicited tenderoffer to acquire the remaining 80.9% interest, which it did not already own, in ZA. Theoffer was conditioned upon at least 50% of ZAs shares being tendered. The transaction wassubject to regulatory approvals.NETHERLANDS - Sanofi-Aventis SA of France planned to launch a challenging tender offer to acquire the remaining 75.12% interest, or 28.648 mil ordinary shares, which it did not already own, in ZentivaNV (ZN), an Amsterdam-based manufacturer of pharmaceuticals, for 43.574 euros (1,050 Czech koruna/$67.568 US) in cash per share, or a total value of 1.248 bil euros (30.080 bil koruna/$1.936 bil).Originally, Anthiarose Ltd of Cyprus, a wholly-owned unit of Prvni Privatizacni Fond AS, planned to launch an unsolicited tender offer to acquire the remaining 80.9% interest, which it did not alreadyown, in ZA. The offer was conditioned upon at least 50% of ZAs shares being tendered. The transaction was subject to regulatory approvals.NETHERLANDS - Sanofi-Aventis SA of France planned to launch a challenging tender offer to acquire the remaining 75.12% interest, or28.648 mil ordinary shares, which it did not already own, in Zentiva NV (ZN), an Amsterdam-based manufacturer of pharmaceuticals, for43.574 euros (1,050 Czech koruna/$67.568 US) in cash per share, or a total value of 1.248 bil euros (30.080 bil koruna/$1.936 bil).Originally, Anthiarose Ltd of Cyprus, a wholly-owned unit of Prvni Privatizacni Fond AS, planned to launch an unsolicited tender offer toacquire the remaining 80.9% interest, which it did not already own, in ZA. The offer was conditioned upon at least 50% of ZAs sharesbeing tendered. The transaction was subject to regulatory approvals.Merrill Lynch & Co Inc1.00000$ 2,869.493 - Merrill Lynch - Adv0.00000Intended44719.000005263.0000028052.0000069002.000008.22500117.60300110.40500180.53700109.9530094.7470069.25100312.2480078.034001.147000.000000.000000.000000.000001.12300352.02600450.86900579.44200337.07900269.11800127.9180043.5880097.4460063.0290050.6340028.3250042.6230060.84700136.6400089.6240074.1200047.2330059.45500514.44600619.35800397.44700335.05100237.35400557.243001246.170001382.62400863.40700651.23300336.96100308.39100Status:IntendedEUR38.8190038.8190.107005.298005.298-17.604006.5360013.6500013.7710021.33500492.2720045.7080045.5130014.1300021.295004.721002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances337714003New YorkFrance2834ForeignPublicSNY2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances830926002LondonNetherlands2834ForeignPublicZEND1935.657001850.536002869.493001466.87100Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/fitch/424185_pr_framefitch/424185_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.AstraZeneca plcBayer AGGlaxoSmithKline plcNovartis AGRoche Deutschland Holding GmbHSanofi-Aventis S.A.8036243480457972804579768045797980457983858840736/18/2008 10:18:00 AM0100000001030000010317000103170385Press ReleaseAZNBAYGSKNOVNSAN424185_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/fitch/423081_pr_framefitch/423081_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Abbott LaboratoriesAstraZeneca plcBayer AGFresenius SEGlaxoSmithKline plcMerck & Company, Inc.Novartis AGPfizer Inc.Roche Deutschland Holding GmbHSanofi-Aventis S.A.Wyeth8009174080360516803613728036159280361630803624348045797280457976804579798045798382151338858840736/9/2008 2:13:00 PM010000000103000001031700010317030104000085Press ReleaseABTAZNBAYFREGSKMRKNOVNPFESANWYE423081_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/fitch/388942_report_framefitch/388942_report_framepdfFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Abbott LaboratoriesAmgen, Inc.AstraZeneca plcBristol-Myers Squibb CompanyEli Lilly & CompanyGlaxoSmithKline plcJohnson & JohnsonMerck & Company, Inc.Novartis AGPfizer Inc.Roche Deutschland Holding GmbHSanofi-Aventis S.A.Schering-Plough CorporationWyeth800917408036051680361372803614198036159280361630803624348041717980457972804579768045797980457983806562368071041080843884850944736/9/2008 10:11:00 AM0100000001030000010317000103170301040000275Special ReportABTAMGNAZNBMYGSKJNJLLYMRKNOVNPFESANSGPWYE388942_report_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-25627780newstex/PRN-0001-25627780xml May ##, #### (Canada NewsWire Group delivered by Newstex) -- EDMONTON, Canada, May ## /CNW/ -- << TCH (Taxotere, Carboplatin, Herceptin) showed a significant improvement in Disease-Free Survival (DFS) and Overall Survival...070000000700100007001004070140000701400807014005070140120400000004002000040020061300000013001000130010025/29/2008 6:15:20 PM18000000180220001900000019001000190020001900200719002018Canada NewsWire GroupPRN-0001-25627780GENENTECH INCSANOFI-AVENTISDNASNYNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1853908ccbn/T1853908norm...Good day everyone and welcome to the Sanofi-Aventis conference call. Today's conference is being recorded. At this time I would like to turn the conference over to your moderator, Mr. Sanjay Gupta. Please go ahead, sir. ... 5/16/2008 8:05:00 PMSanofi-Aventis54.0000FinalSanofi-Aventis - The ATHENA study results on Multaq® - Conference Call TranscriptSNY9:00pm CETTranscriptT1853908Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1853908ccbn/B1853908norm...SNY reported ATHENA study results. Dronedarone, a new channel blocking antiarrhythmic drug with rhythm and rate controlling properties, proved to be effective and safe in reducing cardiovascular outcomes (cardiovascular hospitalization or death) in patients with AF. www.streetevents.comContact Us ... 5/15/2008 9:04:00 PMSanofi-Aventis54.0000EditedSanofi-Aventis - The ATHENA study results on Multaq® - Conference Call SummarySNY9:00pm CETBriefB1853908Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0001-25315345newstex/PRN-0001-25315345xml May ##, #### (Canada NewsWire Group delivered by Newstex) -- VANCOUVER, May ## QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has signed a sale and purchase agreement to sell the land and building comprising its corporate...040000000400200004002006040040000400400304016000040160470700000007014000070140125/15/2008 7:16:37 PM1800000018022000Canada NewsWire GroupPRN-0001-25315345NOVARTIS AGQLT INCSANOFI-AVENTISROBERT NULL BUTCHOFSKYNVSQLTQLTISNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-25193089newstex/PRN-0001-25193089xml May ##, #### (Canada NewsWire Group delivered by Newstex) -- Small study supports the potential for QLT's drug elution technology toreduce and sustain intraocular pressure VANCOUVER, May ## /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT)...0700000007005000130000001301000004000000040020000400200607014000070140120200000002002000020020085/12/2008 8:18:24 AM180000001801800018016000Canada NewsWire GroupPRN-0001-25193089NOVARTIS AGQLT INCSANOFI-AVENTISROBERT NULL BUTCHOFSKYNVSQLTQLTISNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/SINO-0001-25190754newstex/SINO-0001-25190754xml BEIJING, May ##, #### (SinoCast delivered by Newstex) -- Chinese pharmaceutical manufacturer Jiangsu Hengrui Medicine Co., Ltd. (SHSE: ######) announced days ago that it had received a verdict in lawsuit with French pharmaceutical...04000000040180000400200004002006070000000701400007014012110000001101600011016001020000000200200002002004020020065/12/2008 6:19:35 AM18000000180180001900000019003000190020001900200419002009190020131900200719002018SinoCast's China Business Headline NewsSINO-0001-25190754SANOFI-AVENTISSNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-25083540newstex/PRN-0001-25083540xml May #, #### (Canada NewsWire Group delivered by Newstex) -- Health Canada's Preliminary Test of Student's Findings "Encouraging" Ottawa, Toronto, Montreal, Edmonton and Calgary Students Win Canada-wideCompetition Judged by Experts at...08000000080060001100000011006000110080000400000004002000040020010400200605000000050100000501000105005000050050031300000013010000130100051300200013002005070000000701400007014012070030000700300607001000070010075/7/2008 12:23:25 PM18000000180060001801600019000000190030001900200019002012Canada NewsWire GroupPRN-0001-25083540SANOFI-AVENTISSNYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-25077018newstex/BW-0001-25077018xml NEW YORK, May #, #### (Business Wire) -- Bristol-Myers Squibb Company (NYSE:BMY) will present today at the ##rd Annual Deutsche Bank Healthcare Conference. Lamberto Andreotti, Executive Vice President and Chief Operating Officer, will...040000000400600004006005040020000400200604016000040160485/7/2008 9:25:22 AM180000001800400018008000Business WireBW-0001-25077018BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEDEUTSCHE BANK AKTIENGESELLSCHAFTSANOFI-AVENTISLAMBERTO NULL ANDREOTTIBMYBMY PRDBSNYNewsNewstex